Loading patent…
AssigneeUpsher-Smith Laboratories, Inc.
InventorsLori M. Freese, Thomas R. Gorham, Jennifer A. Wheeler-Davis
Estimating the term…
The invention provides a pharmaceutical composition which is a combination of an insulin-secretion stimulant and a HMG-CoA reductase inhibitor. Suitable insulin-secretion stimulants include the sulfonylurea drugs, and suitable HMG-CoA reductase inhibitors include the statin drugs. The composition may be formulated to provide extended-release characteristics of one or both of the active components. Also provided are methods for treating a diabetic patient using a combination of an insulin-secretion stimulant and a HMG-CoA reductase inhibitor. Practice of the methods of the invention may result in the administration of fewer dosages to the patient. The invention also provides a pharmaceutical composition which is a combination of an antihyperglycemic drug, particularly a biguanide compound, in combination with a HMG-CoA reductase inhibitor. Also provided are methods for treating a diabetic patient using a combination of an antihyperglycemic biguanide compound and a HMG-CoA reductase inhibitor.
A pharmaceutical dosage unit comprising a therapeutically effective amount of an insulin secretion stimulant in combination with a HMG-CoA reductase inhibitor.
A pharmaceutical dosage unit comprising about 5 to about 10 milligrams glipizide and about 20 to about 40 milligrams simvastatin.
A method of treating a diabetic patient comprising administering a pharmaceutical dosage unit, the dosage unit including a therapeutically effective amount of an insulin secretion stimulant in combination with a HMG-CoA reductase inhibitor.
A method for reducing the number of dosages administered to a diabetic patient by utilizing a combination of active agents, the method comprising the steps of:
A method of treating a diabetic patient comprising administering to the patient a single dosage unit per day, the dosage unit including both a therapeutically effective amount of an insulin secretion stimulant exhibiting sustained-release characteristics, and a HMG-CoA reductase inhibitor.
A pharmaceutical dosage unit comprising a therapeutically effective amount of an antihyperglycemic biguanide compound in combination with a HMG-CoA reductase inhibitor.
A method of treating a diabetic patient comprising administering a pharmaceutical dosage unit, the dosage unit including a therapeutically effective amount of antihyperglycemic biguanide compound in combination with a HMG-CoA reductase inhibitor.
A method for reducing the number of dosages administered to a diabetic patient by utilizing a combination of active agents, the method comprising the steps of:
A method of treating a diabetic patient comprising administering to the patient a single dosage unit per day, the dosage unit including both a therapeutically effective amount of an antihyperglycemic biguanide compound exhibiting sustained-release characteristics, and a HMG-CoA reductase inhibitor.
Dependencies are inferred from the claim text.